BlackJack3D/iStock via Getty Images Gain Therapeutics ( NASDAQ: GANX ) said on Thursday it was proposing to offer and sell shares of its common stock in an underwritten public offering. Shares of GANX fell 12.2% in extended trading.
The company expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock and pre-funded warrants offered in the offering. GANX plans to use the offering proceeds to continue clinical and nonclinical development of its lead product candidate GT-02287 for the treatment of neurodegenerative diseases including GBA1 Parkinson’s disease and for general corporate purposes. Press Release More on Gain Therapeutics Gain Therapeutics: Phase 1 Readout Awaits For Parkinson's Drug With Great Potential Seeking Alpha’s Quant Rating on Gain Therapeutics Historical earnings data for Gain Therapeutics Financial information for Gain Therapeutics.
